EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Evidence of muscarinic cholinergic receptor in dog portal vein binding of tritium labeled quinuclidinyl benzilate


Life Sciences 32(15): 1757-1764
Evidence of muscarinic cholinergic receptor in dog portal vein binding of tritium labeled quinuclidinyl benzilate
Muscarinic cholinergic receptor sites in dog portal veins were analyzed directly using [3H]quinuclidinyl benzilate (QNB) as a ligand. Specific [3H]QNB binding to crude membrane preparations from the isolated veins was saturable, reversible and of high affinity (Kd = 15.5 .+-. 2.8 pM) with a Bmax [maximum bound concentration] of 110 .+-. 14.7 f[femto]mol/mg protein. Scatchard and Hill plot analyses of the data indicated 1 class of binding sites. From kinetic analysis of the data, association and dissociation rate constants of 1.91 .times. 109 M-1 min-1 and 0.016 min-1, respectively, were calculated. Kd calculated from the equation Kd = K-1/K+1 was 8.3 pM, in good agreement with the Scatchard estimate of Kd (15.5 pM). Specific binding of [3H]QNB was displaced by muscarinic agents. Nicotinic cholinergic agents, .alpha.-bungarotoxin, nicotine and hexamethonium, were ineffective in displacing [3H]QNB binding at 10 .mu.M. These findings provide direct evidence for the existence of muscarinic cholinergic receptors in dog portal veins.

(PDF 0-2 workdays service: $29.90)

Accession: 005411587



Related references

Evidence for muscarinic cholinergic receptors in dog portal vein: binding of [3H]quinuclidinyl benzilate. Life Sciences 32(15): 1757-1763, 1983

Cholinergic muscarinic receptor in synaptosomal membranes heterogeneity of binding sites for l tritium labeled quinuclidinyl benzilate. Molecular Pharmacology 22(2): 304-309, 1982

Tritium labeled pirenzepine and tritium labeled quinuclidinyl benzilate binding to brain muscarinic cholinergic receptors differences in measured receptor density are not explained by differences in receptor isomerization. Molecular Pharmacology 26(2): 164-169, 1984

Comparison of tritium labeled pirenzepine and tritium labeled quinuclidinyl benzilate binding to muscarinic cholinergic receptors in rat brain. Journal of Pharmacology & Experimental Therapeutics 228(3): 648-655, 1984

Correlation between muscarinic receptor concentration measured by tritium labeled quinuclidinyl benzilate binding and in vivo cholinergic sensitivity of cat eyes. Investigative Ophthalmology & Visual Science: 189-190, 1979

Cholinergic muscarinic receptors in rat myocardium properties of tritium labeled quinuclidinyl benzilate binding sites. Indian Journal of Experimental Biology 23(6): 300-305, 1985

Effects of lithium on tritium labeled levo quinuclidinyl benzilate binding to rat brain muscarinic cholinergic receptors. Journal of Neuroscience Research 11(2): 171-178, 1984

Characterization of muscarinic cholinergic receptors in the lower esophageal sphincter of the cat binding of tritium labeled quinuclidinyl benzilate. Gastroenterology 77(6): 1224-1234, 1979

The differential loss of tritium labeled pirenzepine vs. tritium labeled levo quinuclidinyl benzilate binding to soluble rat brain muscarinic receptors indicates that pirenzepine binds to an allo steric state of the muscarinic receptor. Biochemical and Biophysical Research Communications 118(3): 950-957, 1984

Evidence for muscarinic receptors on rat colonic epithelial cells binding of tritium labeled quinuclidinyl benzilate. Journal of Pharmacology & Experimental Therapeutics 218(2): 426-434, 1981